Cardiac biomarkers and survival in haemodialysis patients

被引:99
|
作者
Sommerer, C.
Beimler, J.
Schwenger, V.
Heckele, N.
Katus, H. A.
Giannitsis, E.
Zeier, M.
机构
[1] Univ Hosp Heidelberg, Dept Nephrol, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Dept Cardiol, D-69120 Heidelberg, Germany
关键词
cardiac biomarker; cardiovascular mortality; haemodialysis; hypervolaemia; NT-proBNP; troponin;
D O I
10.1111/j.1365-2362.2007.01785.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In dialysis patients, cardiac troponin T (cTNT) is often elevated despite the absence of acute myocardial ischaemia, and amino-terminal pro-B-natriuretic peptide (NT-proBNP) is markedly higher compared to non-haemodialysis patients. In a longitudinal observation, we evaluated the association of cTNT and NT-proBNP on cardiovascular morbidity and mortality in haemodialysis patients with and without fluid overload. Materials and methods Plasma cTNT levels of 134 haemodialysis patients were measured before and after a dialysis session by 3rd generation electro-chemoluminiscence immunoassay. NT-proBNP was determined using a polyclonal antibody recognizing the N-terminal fragment of BNP (Elecsys autoanalyzer 2010, Roche Diagnostics, Mannheim, Germany). Volume status was determined by a clinical score system. Cardiovascular morbidity and mortality were assessed over a follow-up period of 36 months. Results Plasma cTNT > 0.03 ng mL(-1) was found in 39.6% of all patients. Patients with hypervolaemia had significantly higher cTNT levels compared to euvolaemic patients (median 0.054 ng mL(-1), interquartile range 0.019-0.153 vs. 0.005 ng mL(-1), < 0.001-0.034; P < 0.001). All haemodialysis patients had excessively high levels of NT-proBNP (median 4524; interquartile range 2000-10 250 pg mL(-1)), and NT-proBNP was significantly higher in hypervolaemic haemodialysis patients (11 988, 5307-19 242) compared to euvolaemic haemodialysis patients (3247, 1619-5574); P < 0.001. Receiver operator curves showed a threshold of cTNT > 0.026 ng mL(-1) and NT-proBNP > 5300 pg mL(-1) as predictors of hypervolaemia. Asymptomatic chronic haemodialysis patients with cTNT > 0.026 ng mL(-1) and NT-proBNP > 5300 pg mL(-1) were more likely to die due to cardiac events in the follow-up period. Multivariate analysis documented that elevated cTNT and NT-proBNP levels were highly predictive for cardiovascular events. Conclusions Plasma levels of cTNT are elevated in approximately 40% and NT-proBNP levels in 100% of asymptomatic chronic haemodialysis patients. Both parameters depend on volume status. Increased NT-proBNP and cTNT are strongly associated with adverse outcome in end-stage renal disease patients undergoing haemodialysis, and are a useful tool for risk stratification in chronic haemodialysis patients.
引用
收藏
页码:350 / 356
页数:7
相关论文
共 50 条
  • [21] Interdialytic weight gain and survival in haemodialysis patients
    Viana, Helena
    Resina, Cristina
    Lopes, Joao
    Guerra, Alexandra
    Costa, Teixeira
    Lobos, Ana
    Ramos, Aura
    Remedio, Francisco
    Ribeiro, Francisco
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 240 - 240
  • [22] Illness Perceptions Predict Survival in Haemodialysis Patients
    Chilcot, Joseph
    Wellsted, David
    Farrington, Ken
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2011, 33 (04) : 358 - 363
  • [23] IMPACT OF PERIODONTAL DISEASE ON SURVIVAL OF HAEMODIALYSIS PATIENTS
    Garneata, Liliana
    Slusanschi, Oana
    Dragomir, Diana Ramona
    Corbu-Stancu, Alexandra
    Barbulescu, Carmen
    Mircescu, Gabriel
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 288 - 288
  • [24] QTc dispersion in haemodialysis patients with cardiac complications
    Nakamura, S
    Ogata, C
    Aihara, N
    Sasaki, O
    Yoshihara, F
    Nakahama, H
    Inenaga, T
    Kimura, G
    Kawano, Y
    [J]. NEPHROLOGY, 2005, 10 (02) : 113 - 118
  • [25] Biomarkers of cardiac ischemia, necrosis and inflammation in haemodialysis in predicting all cause mortality
    Gaze, DC
    Crompton, L
    Collinson, PO
    [J]. CLINICAL CHEMISTRY, 2005, 51 : A5 - A5
  • [26] Bone biomarkers in haemodialysis patients: Bone alkaline phosphatase or β-Crosslaps?
    Jean, Guillaume
    Souberbielle, Jean-Claude
    Granjon, Samuel
    Lorriaux, Christie
    Hurot, Jean-Marc
    Mayor, Brice
    Deleaval, Patrik
    Chazot, Charles
    [J]. NEPHROLOGIE & THERAPEUTIQUE, 2013, 9 (03): : 154 - 159
  • [27] Cardiac biomarkers in haemodialysis patients: The prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T
    Sommerer, Claudia
    Giannitsis, Evangelos
    Schwenger, Vedat
    Zeier, Martin
    [J]. NEPHRON CLINICAL PRACTICE, 2007, 107 (03): : C77 - C81
  • [28] THE IMPACT OF ALBUMIN LOOSING TREATMENT ON SURVIVAL OF HAEMODIALYSIS PATIENTS
    Tsuchida, Kenji
    Michiwaki, Hiroyuki
    Minakuchi, Jun
    Kawashima, Shu
    Tomo, Tadashi
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 302 - 302
  • [29] Haemoglobin level and vascular access survival in haemodialysis patients
    Garrancho, JM
    Kirchgessner, J
    Arranz, M
    Klinkner, G
    Rentero, R
    Ayala, JA
    Marcelli, D
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (11) : 2453 - 2457
  • [30] Does erythropoetin improve survival in ESRD haemodialysis patients?
    Shaldon, Stanley
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (03) : 962 - 962